Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Oasmia Pharmaceutical plans deslisting of ADS from Nasdaq US.

Document Cited in Related
Vincent

NORDIC BUSINESS REPORT-August 5, 2019-Oasmia Pharmaceutical plans deslisting of ADS from Nasdaq US

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Oasmia Pharmaceutical AB (Oasmia) (STO:OASM.ST) (FRA:OMAX.GR) announced on Saturday that it intends to delist its American Depositary Shares (ADS) from the Nasdaq Capital Market and to deregister and terminate its reporting obligations with the Securities and Exchange Commission (SEC).

Oasmia expects this delisting to become effective on or about 22 August 2019.

According to the company, the main purpose of the delisting is to reduce complexity in financial reporting and administrative costs.

Oasmia added that it remains committed to serving its investor base in the US and to maintaining the highest standards for corporate governance. The company will continue to serve its US investors through its investor relations team.

Also, Oasmia is considering maintaining an American Depositary Receipt programme on a level I basis, which is presumed to allow investors to hold their securities in the form of ADS. Oasmia's ordinary shares will continue to trade on Nasdaq Stockholm.

Reportedly, the company plans to submit a Form 25...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT